CorMedix (CRMD) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed CorMedix (CRMD) over the past year, losing 15.0% versus a loss of 34.4%. Over five years, MNPR leads with a +241.3% price change compared with +47.1% for CRMD. CorMedix is the larger company by market cap ($567.4 million vs $562.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | MNPR |
|---|---|---|
| Share price | $7.28 | $83.78 |
| Market cap | $567.43M | $562.35M |
| 1-day change | 0.00% | +5.29% |
| YTD return | -37.40% | +28.30% |
| 1-year return | -34.36% | -14.96% |
| 5-year return | +47.07% | +241.26% |
| P/E ratio (TTM) | 3.55 | — |
| Forward P/E | 20.80 | — |
| EPS (TTM) | $2.05 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $124.82 |
| 52-week low | $6.13 | $50.07 |
| Distance from 52-week high | -44.09% | -32.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +110.58% | +55.07% |
| Average volume | 1.06M | 218.50K |
| Shares outstanding | 77.94M | 6.71M |
| Employees | 191 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed CRMD by 19.4 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CRMD vs MNPR FAQ
Which is bigger, CorMedix or Monopar Therapeutics?
CorMedix (CRMD) is larger, with a market capitalization of $567.43M compared with $562.35M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, CRMD or MNPR?
MNPR returned -14.96% over the past 12 months, compared with -34.36% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.